Cipla to make version of Relenza for Indian market

02/21/2006 | Business Standard (India)

India's Cipla announced it will manufacture zanamivir, currently sold by GlaxoSmithKline under the name Relenza. GSK recently received permission to import the anti-flu drug to India, but a GSK official said its European production capacity may not be sufficient in the short term and licensing of the drug to other firms has not been decided.

View Full Article in:

Business Standard (India)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Marlborough, MA
Test Technician
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT